Oral administration of nanozyme-armed probiotic Escherichia coli Nissle 1917 with ROS scavenging for inflammatory bowel disease therapy - Pharma Excipients

Oral administration of nanozyme-armed probiotic Escherichia coli Nissle 1917 with ROS scavenging for inflammatory bowel disease therapy - Pharma Excipients

Abstract Inflammatory bowel disease (IBD) represents a group of chronic, non-specific gastrointestinal disorders characterized by pathological overproduction of reactive oxygen species (ROS). Current therapeutic interventions, including conventional drugs and oral probiotics, are frequently limited by their vulnerability to the harsh gastrointestinal environment. To address these challenges, we have developed a novel engineered bacterium, design…